Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

ClinicalTrials.gov ID: NCT03409107

Public ClinicalTrials.gov record NCT03409107. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 11:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo

Study identification

NCT ID
NCT03409107
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
614 participants

Conditions and interventions

Conditions

Interventions

  • Daprodustat (GSK1278863) Drug
  • Placebo Drug
  • Iron therapy Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 4, 2018
Primary completion
Oct 6, 2020
Completion
Oct 6, 2020
Last update posted
Apr 1, 2024

2018 – 2020

United States locations

U.S. sites
49
U.S. states
20
U.S. cities
47
Facility City State ZIP Site status
GSK Investigational Site Homewood Alabama 35209
GSK Investigational Site Little Rock Arkansas 72204
GSK Investigational Site Downey California 90242
GSK Investigational Site Fresno California 93720
GSK Investigational Site Lynwood California 90262
GSK Investigational Site Northridge California 91324
GSK Investigational Site Northridge California 91325
GSK Investigational Site Riverside California 82503
GSK Investigational Site Salinas California 93901
GSK Investigational Site Santa Ana California 92704
GSK Investigational Site Denver Colorado 80230
GSK Investigational Site Hartford Connecticut 06112
GSK Investigational Site Middlebury Connecticut 06762
GSK Investigational Site Coral Springs Florida 33067
GSK Investigational Site Hollywood Florida 33024
GSK Investigational Site Kissimmee Florida 34741
GSK Investigational Site Lauderdale Lakes Florida 33313
GSK Investigational Site Pembroke Pines Florida 33028
GSK Investigational Site Tampa Florida 33614
GSK Investigational Site Adairsville Georgia 30103
GSK Investigational Site Macon Georgia 31201
GSK Investigational Site Macon Georgia 31217
GSK Investigational Site Statesboro Georgia 30458
GSK Investigational Site Indianapolis Indiana 46260
GSK Investigational Site Overland Park Kansas 66210
GSK Investigational Site Buckley Michigan 49620
GSK Investigational Site Detroit Michigan 48202
GSK Investigational Site Saint Clair Shores Michigan 48081
GSK Investigational Site Brookhaven Mississippi 39601
GSK Investigational Site St Louis Missouri 63136
GSK Investigational Site Rochester New Hampshire 03867
GSK Investigational Site Asheville North Carolina 28801
GSK Investigational Site Charlotte North Carolina 28262
GSK Investigational Site Durham North Carolina 27704
GSK Investigational Site Midwest City Oklahoma 73130
GSK Investigational Site Oklahoma City Oklahoma 73112
GSK Investigational Site Beaver Pennsylvania 15009
GSK Investigational Site Duncansville Pennsylvania 16635
GSK Investigational Site Scottdale Pennsylvania 15683
GSK Investigational Site Smithfield Pennsylvania 15478
GSK Investigational Site West Reading Pennsylvania 19611
GSK Investigational Site Orangeburg South Carolina 29118
GSK Investigational Site Kingsport Tennessee 37660
GSK Investigational Site Memphis Tennessee 38163
GSK Investigational Site DeSoto Texas 75115
GSK Investigational Site El Paso Texas 79935
GSK Investigational Site McAllen Texas 78503
GSK Investigational Site Waxahachie Texas 75165
GSK Investigational Site Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 119 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03409107, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 1, 2024 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03409107 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →